- Home
- TEAF vs CRVS Comparison
TEAF vs CRVS Comparison
Compare TEAF & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- CRVS
- Stock Information
- Founded
- TEAF 2017
- CRVS 2014
- Country
- TEAF United States
- CRVS United States
- Employees
- TEAF N/A
- CRVS N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- TEAF Finance
- CRVS Health Care
- Exchange
- TEAF Nasdaq
- CRVS Nasdaq
- Market Cap
- TEAF 160.4M
- CRVS 305.4M
- IPO Year
- TEAF N/A
- CRVS 2016
- Fundamental
- Price
- TEAF $12.27
- CRVS $3.91
- Analyst Decision
- TEAF
- CRVS Strong Buy
- Analyst Count
- TEAF 0
- CRVS 4
- Target Price
- TEAF N/A
- CRVS $15.00
- AVG Volume (30 Days)
- TEAF 56.1K
- CRVS 1.2M
- Earning Date
- TEAF 01-01-0001
- CRVS 08-05-2025
- Dividend Yield
- TEAF 9.20%
- CRVS N/A
- EPS Growth
- TEAF N/A
- CRVS N/A
- EPS
- TEAF N/A
- CRVS N/A
- Revenue
- TEAF N/A
- CRVS N/A
- Revenue This Year
- TEAF N/A
- CRVS N/A
- Revenue Next Year
- TEAF N/A
- CRVS N/A
- P/E Ratio
- TEAF N/A
- CRVS N/A
- Revenue Growth
- TEAF N/A
- CRVS N/A
- 52 Week Low
- TEAF $11.11
- CRVS $1.75
- 52 Week High
- TEAF $13.30
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- TEAF 60.41
- CRVS 55.29
- Support Level
- TEAF $11.79
- CRVS $3.55
- Resistance Level
- TEAF $12.04
- CRVS $4.38
- Average True Range (ATR)
- TEAF 0.12
- CRVS 0.31
- MACD
- TEAF 0.00
- CRVS -0.01
- Stochastic Oscillator
- TEAF 73.91
- CRVS 61.68
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a USA-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).